1. Home
  2. SAM vs RAPP Comparison

SAM vs RAPP Comparison

Compare SAM & RAPP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Boston Beer Company Inc. (The)

SAM

Boston Beer Company Inc. (The)

HOLD

Current Price

$182.40

Market Cap

1.9B

ML Signal

HOLD

RAPP

Rapport Therapeutics Inc.

HOLD

Current Price

$46.22

Market Cap

1.8B

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
SAM
RAPP
Founded
1984
2022
Country
United States
United States
Employees
N/A
N/A
Industry
Beverages (Production/Distribution)
Sector
Consumer Staples
Exchange
Nasdaq
Nasdaq
Market Cap
1.9B
1.8B
IPO Year
1996
2024

Fundamental Metrics

Financial Performance
Metric
SAM
RAPP
Price
$182.40
$46.22
Analyst Decision
Hold
Strong Buy
Analyst Count
11
6
Target Price
$233.70
$48.50
AVG Volume (30 Days)
297.8K
293.5K
Earning Date
04-30-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
95.45
24.34
EPS
N/A
N/A
Revenue
$1,964,994,000.00
N/A
Revenue This Year
$1.02
N/A
Revenue Next Year
$1.31
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$158.68
$13.86
52 Week High
$264.46
$48.00

Technical Indicators

Market Signals
Indicator
SAM
RAPP
Relative Strength Index (RSI) 51.08 63.70
Support Level $166.11 $38.95
Resistance Level $188.90 N/A
Average True Range (ATR) 6.47 2.24
MACD 0.41 0.40
Stochastic Oscillator 69.17 77.45

Price Performance

Historical Comparison
SAM
RAPP

About SAM Boston Beer Company Inc. (The)

Boston Beer is a top player in high-end malt beverages and adjacent categories in the US, with strong positions in craft beer, flavored malt beverages, hard cider, and hard seltzer. The bulk of volume and revenue is concentrated in four brands: Samuel Adams, Angry Orchard, Twisted Tea, and Truly. Beverages are produced using a hybrid model leveraging both in-house capacities and third-party breweries through contract arrangements. While the firm is required to use distributors to reach end markets, including retailers and on-premises operators, it also employs 500 internal sales representatives to educate the market about its products. The firm generates almost all sales in the US.

About RAPP Rapport Therapeutics Inc.

Rapport Therapeutics Inc is a clinical-stage biotechnology company dedicated to the discovery and development of small-molecule precision medicines for patients with neurological or psychiatric disorders. The company's portfolio of programs from its RAP technology platform includes RAP-219, an investigational small molecule being developed as a therapy for focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania. Additionally, it has two discovery-stage nicotinic acetylcholine receptor (nAChR) programs stemming from its RAP technology platform: one being developed for the treatment of chronic pain, and the second, being developed for the treatment of hearing disorders. Geographically, the company operates in the United States.

Share on Social Networks: